

# Willingness and Preferences for Long-Acting Injectable PrEP Among U.S. Men Who Have Sex with Men: A Discrete Choice Experiment - EPC191

S Wilson Beckham<sup>1</sup>, Connor Volpi<sup>1</sup>, Travis Sanchez<sup>2</sup>, Supriya Sarkar<sup>3</sup>, Vani Vannappagari<sup>3</sup>, Alex Rinehart<sup>3</sup>, M Keith Rawlings<sup>3</sup>, Patrick S Sullivan<sup>2</sup>

## Introduction

Clinical trials have demonstrated that cabotegravir long-acting injectable HIV pre-exposure prophylaxis (LA-PrEP) has superior efficacy compared to daily oral PrEP and a good safety profile. Understanding preferences for LA-PrEP among people who could benefit from PrEP is important to increase uptake and persistence.

## Methods

Willingness to use and preferences for LA-PrEP were measured in 5,982 HIV-negative or unknown status, sexually active cis-gender men who have sex with men (MSM) 15+ years in the 2020 American Men's Internet Survey.

43.8% of MSM (n=2,621) took a discrete choice experiment (DCE) with paired profiles of hypothetical LA-PrEP alternatives: out-of-pocket cost (\$10, \$30, \$50, \$75), side effects (25% chance of pain, 15% chance of headache, 5% chance of rash), level of protection (90.0%, 95.0%, 99.9%), and total clinic time (1, 2, 3 hours), with an opt-out option.

Multinomial logit calculated mean coefficients representing preferences, which were then calculated into relative importance of attributes.


## Participant Details




64% <30 years old  
64% White / 9% Black / 19% Hispanic  
78% ≥some university education  
60% urban or suburban  
---  
13% current oral PrEP use  
15% past oral PrEP use

## Results

### Among 5,982 HIV-negative US-based MSM:



### Among 2,621 DCE Respondents:



The **most important** LA-PrEP attributes were **level of protection** and **out-of-pocket costs**, relative to clinic time spent and side effects.

A large negative alternative-specific constant (-8.55) indicates that **MSM largely prefer LA-PrEP, regardless of attributes**, to not having LA-PrEP at all.

## Recommendations

A large proportion of MSM expressed a preference for LA PrEP over daily oral PrEP pills. High efficacy of LA PrEP was most valued by MSM and could encourage its use, as would lower out of pocket costs.

These results can help guide tailored interventions to increase intervention acceptability and effectiveness among this population.

## Affiliations & Acknowledgments

1. Health Behavior & Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
2. Epidemiology, Emory Rollins School of Public Health, Atlanta, USA
3. ViiV Healthcare, Research Triangle Park, USA

Study Contact:  
S Wilson Beckham  
sbeckha4@jh.edu

**This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their licence. In some cases, the scientific Information requested and downloaded may relate to the use of our medicine(s) outside of their license.**